Skip to content
User

Parnassus Endeavor Fund AZN trades

Parnassus Investments

Parnassus Endeavor Fund AstraZeneca PLC stake

total: 120

Trades details

Total transactions:
3
New positions:
1
Added:
1
Reduced:
1
Held since:
2026 Q1
Held for:
3 quarters
Latest activity:
2026 Q3
According to 2026 Q3 report, Parnassus Endeavor Fund holds 739,613 AstraZeneca PLC (AZN) shares with a market value of roughly $119.43M accounting for 2.34% of the overall portfolio. To date, the estimated cost basis is nearly $191.57 for "buy" trades and estimated average "sell" price is $189.62. Parnassus Endeavor Fund first purchased AZN in 2026 Q1, initially acquiring 634,492 shares. Since the initial investment in AstraZeneca PLC (AZN), Parnassus Endeavor Fund has made 2 more transactions.

How many AZN shares does Parnassus Endeavor Fund currently hold?

According to 2026 Q3 report, Parnassus Endeavor Fund holds 739,613 shares of AstraZeneca PLC (AZN), valued at around $119.43M.

When did Parnassus Endeavor Fund buy AstraZeneca PLC (AZN)?

Parnassus Endeavor Fund first invested in AstraZeneca PLC (AZN) in 2026 Q1 at the reported quarter-end price of $197.22 per share.

What's the cost basis of Parnassus Endeavor Fund's AZN stake?

The estimated cost basis for AstraZeneca PLC (AZN) stake is around $191.57 per share. This represents their average reported price* across all buy transactions

Estimated cost basis*

Weighted AVG buy price:
$191.57
Weighted AVG sell price:
$189.62

Parnassus Endeavor Fund's historical trades in AstraZeneca PLC

3 results
Period % of
portfolio
Shares
held after*
Reported
price*
Value* % (shares)
of activity
% change
to portfolio
2026 Q3
2.34%
739,613
$161.47
$119,425,311
+19.18% (+119,044)
+0.38%
2026 Q2
2.23%
620,569
$189.62
$117,672,294
-2.19% (-13,923)
-0.06%
2026 Q1
2.71%
634,492
$197.22
$125,134,512
new
+2.71%
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.